autoimmunity occurs when individuals develop antibodies called autoantibodies to their own tissues or self antigens
1.1 Lupus
- chronic, affect skin, joints, heart, lungs, blood, kidneys, brain
- risk factor: 90% woman, 15~44
- types: systematic, cutaneous, drug-induced, neonatal
- systematic lupus erythematosus (SLE):
- 70%
- 1/2 SLE develop severe heart lungs kidneys brain diseases
- signs & symptoms: fatigue, arthritis, fever, butterfly rash across cheeks and nose, photosensitivity, mouth or nose ulcers, fingers turn white/blue when cold (Secondary Raynaud’s phenomenon)
- Cutaneous or discoid lupus:
- 10%
- only affect skin
- signs & symptoms: discoid rash: raised, scaly, red rash, but not itchy, circular; butterfly rash across cheeks and nose; rash on face neck scalp mouth nose vagina
- 10% of cutaneous lupus will develop SLE
- drug-induced lupus erythematosus (DILE):
- 10%
- 70+ prescription drugs: hydralazine (for high blood pressure), procainamide and quinidine (for irregular heart rythm), certain drugs entail a high risk
- signs & symptoms: similar to SLE, but rarely affects organs, will disappear within days to months after discontinuing
- Neonatal Lupus:
- acquired from maternal autoantibodies, affect skin heart blood
- signs & symptoms: rash within several weeks of life, persists about 6 months
- etiology: idiopathic, environmental (infections, sulfa antibiotics, penicillin, UV, stress, certain drugs, hormones(ss grow severe before menstrual periods or during pregnancy, estrogen may)) and genetic may
- diagnosis:
- no testing will confirm
- CBC, urinalysis, autoantibody testing, general level of inflammation, biopsy
- characters:
- chronic, relapsing, often with symptom-free remissions that can last for years
- incurable, challenging management
- most patients live a normal lifespan
- patient care:
- limit exposure to sunlight, tobacco, stress and fatigue
- health diet, exercise, take care of fevers over 100 (37.8)
- treatment:
- for control
- NSAIDs, corticosteroids, antimalarial medications, immunosuppressive drugs, monoclonal antibodies to inhibit autoantibody and antibody production
1.2 Scleroderma
- chronic disease of connective tissue
- risk: women, 40s

- localized form (LSc): affects only the skin
- signs & symptoms: waxy patches (morphea) or streaks on the skin
- tends to regress or stop progressing without treatment
- normal lifespan
- systemic form (SSc): involves internal organs and the skin
- limited cutaneous SSc (lcSSc)
- skin tightening confined to fingers, hands, arms below the elbows; may involve feet and legs below the knees
- 10yr survival rate: 71%
- diffuse cutaneous SSc (dcSSc)
- skin tightening lcSSc+trunk, above the elbows, on the knees
- 10yr survival rate: 21%
- both affect internal organs, but dcSSc are at a greater risk for significant organ dysfunction
- common initial ss: secondary raynaud’s, thickening & tightening of the skin of the fingers, pain in 2+ joints
- early symptoms: heartburn, difficulty swallowing, shortness of breath
- etiology: idiopathic
- immune: stimulate fibroblasts to produce too much collagen
- environmental & genetic: exposure to viral infections & chemicals to who are genetically predisposed
- hormonal: women 4x (estrogen)
- diagnosis:
- history, physical exam
- autoantibody testing and biopsy
- treatment: no cure
- no tobacco, bo cold & stress
- exercise
- small frequent meals
- moisture skin
- cannot be prevented
- control: anti-inflammatory drugs, immunosuppressive drugs, vasodilators to treat raynaud’s
1.3 Sjogren’s Syndrome
- chronic, slow progressive, affects the exocrine glands
- risk factor: 90% women
- primary Sjogren’s syndrome
- secondary Sjogren’s syndrome: occur along with rheumatoid arthritis, lupus, scleroderma
- signs & symptoms:
- dry eyes and mouth
- complications in kidneys, gastrointestinal system, blood vessels, lungs, liver, pancreas, and CNS
- etiology: idiopathic
- environmental: viral infections
- genetic: first-degree relative with autoimmunity disease
- hormone: women during childbearing years
- diagnosis:
- treatment: